CN103655854A - 治疗静脉输液致静脉炎的外敷药及使用方法 - Google Patents
治疗静脉输液致静脉炎的外敷药及使用方法 Download PDFInfo
- Publication number
- CN103655854A CN103655854A CN201210344706.0A CN201210344706A CN103655854A CN 103655854 A CN103655854 A CN 103655854A CN 201210344706 A CN201210344706 A CN 201210344706A CN 103655854 A CN103655854 A CN 103655854A
- Authority
- CN
- China
- Prior art keywords
- percent
- medicine
- grams
- external application
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000001297 phlebitis Diseases 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims abstract description 8
- 238000001990 intravenous administration Methods 0.000 title abstract description 9
- 238000001802 infusion Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 7
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 5
- 230000003203 everyday effect Effects 0.000 claims abstract description 4
- 244000173853 Sanguisorba officinalis Species 0.000 claims abstract description 3
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 7
- 241001057584 Myrrha Species 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 235000001892 vitamin D2 Nutrition 0.000 claims description 6
- 244000080767 Areca catechu Species 0.000 claims description 5
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 4
- 239000011653 vitamin D2 Substances 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 18
- 230000008961 swelling Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 239000011248 coating agent Substances 0.000 abstract description 8
- 238000000576 coating method Methods 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 244000235603 Acacia catechu Species 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229910052602 gypsum Inorganic materials 0.000 abstract 2
- 239000010440 gypsum Substances 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- -1 Conair Chemical compound 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000008687 shenqi fuzheng Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000023959 tonsil neoplasm Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗静脉输液致静脉炎的外敷药，其特征在于：按重量百分比为：川军12-16%、石膏12-16%、地榆12-16%、没药8-12% 、儿茶12-16%、冰片4-7%、寒水石12-16%、黄柏12-16%，各原料药的重量百分比之和为100％，共研细面过80目筛混合均匀配制而成，混匀后置于清洁盒内备用，所说的治疗静脉输液致静脉炎的外敷药的使用方法，其特征在于：使用时，根据患处面积大小，取上述药面加适量香油调匀成糊状，均匀涂于稍大于静脉炎面积的范围，药厚1mm左右，然后将外裹保鲜膜，一次30-60分钟，每日1-2次，本发明具有清热解毒，活血化瘀，止痛、消肿等功效，药品组方科学合理，生产工艺简单，疗效确切、明显，成本低，使用方便，病人宜于接受，无毒副作用。
Description
技术领域
本发明属中草药医药技术领域，具体的说涉及一种治疗静脉输液致静脉炎的外敷药及使用方法。
背景技术
静脉输液是一种有效治疗疾病中最常用的一种治疗手段和方法。然而，静脉输液致静脉炎发生率较高，给患者带来痛苦，轻则引起肢体红肿、热、疼痛、造成再次静脉穿刺困难，影响药液的顺利输入，重则溃烂、坏死继而延误治疗，严重影响患者生命质量。因而治静脉输液致静脉炎相当重要。目前国内治疗此种并发症的主要方法有西药外涂、静脉炎敷贴、紫外线理疗等，但见效慢或医疗费用高或不方便。
发明内容
本发明的目的是克服上述存在的缺点，而提供一种治疗疗程短、疗效高、对人体无疼痛、无毒副作用、价格低廉的治疗静脉输液致静脉炎的外敷药及制备方法。实现本发明的目的所采取的技术方案是：该治疗静脉输液致静脉炎的外敷药按重量百分比为：川军12-16%、 石膏12-16% 、地榆12-16%、 没药8-12% 、儿茶12-16% 、 冰片4-7% 、寒水石12-16% 、黄柏12-16%，各原料药的重量百分比之和为100％，共研细面过80目筛混合均匀配制而成，混匀后置于清洁盒内备用。使用时，取药面加适量香油调和，外敷。本发明制得的外敷药的应用方法立足治疗。其中，川军=大黄，清湿热、凉血、祛瘀、解毒等功效。石膏清热、收敛、生肌，降低血管通透性而起消炎作用。地榆含有大量鞣质，有较强的收敛性和收缩血管的作用，可降低血管的通透性，减少炎性渗出，同时还有明显的杀菌作用。没药活血止痛，消肿生肌。儿茶收湿、生肌敛疮。冰片味辛苦,性凉, 清热透皮，有止痛防腐作用,。寒水石清热泻火，消肿。黄柏具有清热解毒,活血化瘀,去腐生肌的功效,
本发明的优点是：本药方具有清热解毒，活血化瘀，止痛、消肿等功效，药品组方科学合理，生产工艺简单，疗效确切、明显，成本低，使用方便，病人宜于接受，无毒副作用。
具体实施方式
该治疗静脉输液致静脉炎的外敷药按重量百分比为：川军12-16%、 石膏12-16% 、地榆12-16%、 没药8-12% 、儿茶12-16% 、 冰片4-7% 、寒水石12-16% 、黄柏12-16%，各原料药的重量百分比之和为100％，共研细面过80目筛混合均匀配制而成，混匀后置于清洁盒内备用。所说的治疗静脉输液致静脉炎的外敷药每份按重量计：川军15克 、 石膏15克、 地榆15克、没药10克 、 儿茶15克 、 冰片6克 、 寒水石15克 、 黄柏15克共研细面过80目筛混合均匀配制而成。
使用时，根据患处面积大小，取药面加适量香油调匀成糊状，均匀涂于稍大于静脉炎面积的范围，药厚1 mm左右，然后将外裹保鲜膜，一次30-60分钟，每日1-2次。
下面用几个实际例子进一步说明本发明的应用效果。
例1：楚××，女，75岁，住院号12055643，身份证号372425193611195520，患者宫颈癌9年，扁桃体恶性肿瘤半月，2012年7月16日强化CT，检查中，造影剂（优维显）外渗，造成右手、右前臂高度肿胀，针眼处渗血、渗液，疼痛数字评分10分，立即涂药，24小时时疼痛消失，仅右手背轻度肿胀，又涂药一次，于外渗48小时时疼痛、肿胀完全消失，患者未再述任何不适，手、臂未见任何异常。本患者共涂药2次。
例2：张××，男，42岁，住院号1243448，身份证号370121197003250535，患者左颞叶胶质瘤术后1月，长期静脉输液，曾尼莫司汀等药物化疗及甘露醇、果糖、参芪扶正、头孢替安等药物静脉输入，双手疼痛、中度肿胀，右手有3cm长血管条索样改变，左手涂药1次，右手涂药3次（第一天，上、下午各一次，第二天上午一次），不适症状消失，条索样血管变柔软。
3、张××，男，48岁，住院号12050650，身份证号3701041960902131x，患者胃癌术后一余年，长期静脉输液史，曾多疗程化疗。近期双下肢大隐静脉因输入中/长链脂肪乳注射液、18种氨基酸、钠、钾、镁等药物。出现从足踝至膝血管约20cm长条索样改变，伴双下肢轻度肿胀，沉重感，数字疼痛评分2分。一直用喜疗妥外涂一日两次，效果差，改用本自制药物外涂，每日早晚各1次，第三次用药后，肿胀明显减轻，血管条索样改变明显，疼痛数字评分1分。
4、曹××，男，70岁，住院号12049469，身份证370823194108182011，喉癌1+年，长期静脉输液史，近期曾头孢哌酮、舒巴坦、硫辛酸、喘啶等药物静脉点滴。出现双手背疼痛、肿胀、皮下淤血、血管3cm长条索样改变，静脉炎Ⅳ级，右手背涂药1次，左手背涂药3次（每次间隔6-8小时），双手无疼痛，肿胀、皮下瘀血消失、血管柔软如常。
5、王××，男，63岁，住院号12043806，身份证372525194907145231，患者左扁桃体肿瘤1+年，长期静脉输液史。曾顺泊，多西他赛药及氟氯西林、12种复合维生素、硫辛酸等药物静脉输液。右手背肿胀，瘀血，从手背至前臂沿血管走形部位20cm疼痛；左手2cm硬结、瘀血、肿胀。双手背疼痛，数字评分4—5分；两次用药后，疼痛、肿胀、瘀血减轻，后因出院未再继续观察。
6、张××，男，33岁，住院号12052661，身份证372501197809301213，患者确诊脑胶质瘤1+月，全脑放疗，平时甘露醇、康艾、氨曲南等药物静脉点滴，双手及前臂因输液感疼痛、麻木、肿胀，用药1次后症状明显减轻，之后早晚各1次，共4次后不适症状消失。
7、孟××，女，75岁，住院号12056666，身份证370105193702262561，贲门癌化疗1周期，既往冠心病、高血压病史10余年，患者外周血管条件差，在静脉输注5%GDW250ml,康艾40ml液体时，因血管通透性高，出现液体渗漏，造成右手背高度肿胀、疼痛，给予局部本药物涂抹，24h后肿胀消退，疼痛消失。
Claims (3)
1.一种治疗静脉输液致静脉炎的外敷药，其特征在于：按重量百分比为：川军12-16%、 石膏12-16% 、地榆12-16%、 没药8-12% 、儿茶12-16% 、 冰片4-7% 、寒水石12-16% 、黄柏12-16%，各原料药的重量百分比之和为100％，共研细面过80目筛混合均匀配制而成，混匀后置于清洁盒内备用。
2.按照权利要求1所说的治疗静脉输液致静脉炎的外敷药，其特征在于：所说的每份按重量计：川军15克 、 石膏15克、 地榆15克、没药10克 、 儿茶15克 、 冰片6克 、 寒水石15克 、 黄柏15克共研细面过80目筛混合均匀配制而成。
3.一种权利要求1所说的治疗静脉输液致静脉炎的外敷药的使用方法，其特征在于：使用时，根据患处面积大小，取上述药面加适量香油调匀成糊状，均匀涂于稍大于静脉炎面积的范围，药厚1 mm左右，然后将外裹保鲜膜，一次30-60分钟，每日1-2次。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210344706.0A CN103655854B (zh) | 2012-09-18 | 2012-09-18 | 治疗静脉输液致静脉炎的外敷药及使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210344706.0A CN103655854B (zh) | 2012-09-18 | 2012-09-18 | 治疗静脉输液致静脉炎的外敷药及使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655854A true CN103655854A (zh) | 2014-03-26 |
| CN103655854B CN103655854B (zh) | 2015-10-07 |
Family
ID=50295413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210344706.0A Expired - Fee Related CN103655854B (zh) | 2012-09-18 | 2012-09-18 | 治疗静脉输液致静脉炎的外敷药及使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655854B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225526A (zh) * | 2014-08-28 | 2014-12-24 | 王萍 | 一种治疗输液后皮肤瘀肿的中药组合物 |
| CN105560584A (zh) * | 2016-01-20 | 2016-05-11 | 王发芬 | 一种影像科治疗ct扫描造影剂外渗的中药及制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006005924U1 (de) * | 2006-04-10 | 2007-05-16 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung zur Behandlung von Rhinitis |
| CN101926868A (zh) * | 2010-09-06 | 2010-12-29 | 韩淑红 | 一种预防和治疗化疗药物所致静脉炎的外用中药 |
-
2012
- 2012-09-18 CN CN201210344706.0A patent/CN103655854B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006005924U1 (de) * | 2006-04-10 | 2007-05-16 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung zur Behandlung von Rhinitis |
| CN101926868A (zh) * | 2010-09-06 | 2010-12-29 | 韩淑红 | 一种预防和治疗化疗药物所致静脉炎的外用中药 |
Non-Patent Citations (3)
| Title |
|---|
| 丁莲英等: "利多卡因与寒水石治疗百特输液器持续输入5-Fu所致静脉炎的临床观察", 《包头医学院学报》 * |
| 刘永华等: "治疗烫伤验方", 《中国民间疗法》 * |
| 董桂晨等: "黄柏煎剂外敷治疗静脉炎效果观察", 《山西护理杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225526A (zh) * | 2014-08-28 | 2014-12-24 | 王萍 | 一种治疗输液后皮肤瘀肿的中药组合物 |
| CN105560584A (zh) * | 2016-01-20 | 2016-05-11 | 王发芬 | 一种影像科治疗ct扫描造影剂外渗的中药及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103655854B (zh) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230493B (zh) | 一种治疗创口不愈的中药组合物 | |
| CN101703651B (zh) | 一种治疗糖尿病坏疽的药物 | |
| CN103041177B (zh) | 一种治疗糖尿病足的中药 | |
| CN103655854B (zh) | 治疗静脉输液致静脉炎的外敷药及使用方法 | |
| CN103977113B (zh) | 一种治疗糖尿病足的中药 | |
| CN102872187B (zh) | 一种外用毒疮膏及其制备方法 | |
| CN102274372B (zh) | 一种治疗外伤骨折风湿及各种出血的中药 | |
| CN104706919B (zh) | 一种治疗体表溃疡的药物组合物 | |
| CN102743587A (zh) | 一种外用创伤修复液 | |
| CN104524471A (zh) | 一种消肿止痛膏 | |
| CN105327290B (zh) | 一种治疗糖尿病坏疽的外用中药及其制备方法 | |
| CN105343423B (zh) | 一种治疗湿疹的药物及其制备方法 | |
| CN110403995B (zh) | 治疗浅静脉炎作用的中药组合物及制备、使用方法和应用 | |
| CN107898831A (zh) | 用于治疗糖尿病足的外敷中药组合物以及制备方法 | |
| CN108066466A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法与应用 | |
| CN101559185A (zh) | 一种治疗下肢静脉曲张的外用药物 | |
| CN102526382A (zh) | 一种消肿止痛的膏药 | |
| CN101983681A (zh) | 一种治疗白带异常的药剂 | |
| CN104840624A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
| CN104524017A (zh) | 一种治疗脉管炎的中药制剂 | |
| CN1178654C (zh) | 氯霉素冻疮膏 | |
| CN105079204A (zh) | 一种治疗风湿性及类风湿性关节炎的药物及其制备方法 | |
| CN115569173A (zh) | 一种用于治疗糖尿病足的药物 | |
| CN114129622A (zh) | 一种治疗烧烫伤的组合物、其制剂、制备方法及应用 | |
| CN104069393A (zh) | 一种快速治愈伤口溃烂不愈合的药膏及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151113 Address after: 250012 Shandong, Lixia District, Ji'nan Province Cultural Road West, No. 107 Patentee after: Shandong Qilu Hospital Address before: Three ward, Department of radiotherapy, Qilu Hospital,, 107 west Wenhua Road, Lixia District, Shandong, Ji'nan, China. 250012 Patentee before: Han Lili |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151007 Termination date: 20160918 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |